Comparing Theravance Biopharma (TBPH) and Its Rivals

Theravance Biopharma (NASDAQ:TBPH) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it compare to its peers? We will compare Theravance Biopharma to similar businesses based on the strength of its institutional ownership, analyst recommendations, risk, valuation, dividends, profitability and earnings.

Institutional and Insider Ownership

99.1% of Theravance Biopharma shares are owned by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.6% of Theravance Biopharma shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk & Volatility

Theravance Biopharma has a beta of 0.25, suggesting that its stock price is 75% less volatile than the S&P 500. Comparatively, Theravance Biopharma’s peers have a beta of -4.29, suggesting that their average stock price is 529% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Theravance Biopharma and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Theravance Biopharma Competitors	7752	13841	25687	1031	2.41

Theravance Biopharma presently has a consensus target price of $19.00, indicating a potential upside of 11.57%. As a group, “Pharmaceuticals” companies have a potential upside of 23.94%. Given Theravance Biopharma’s peers stronger consensus rating and higher possible upside, analysts plainly believe Theravance Biopharma has less favorable growth aspects than its peers.

Profitability

This table compares Theravance Biopharma and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Theravance Biopharma Competitors	-2,380.91%	-221.73%	-15.99%

Earnings and Valuation

This table compares Theravance Biopharma and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	$105.89 million	16.86
Theravance Biopharma Competitors	$3.54 billion	$3.16 billion	545.52

Theravance Biopharma’s peers have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Theravance Biopharma peers beat Theravance Biopharma on 8 of the 13 factors compared.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.